Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure

MT Newswires Live

Mar 31, 2025

Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioid exposure.

The company said the FDA's feedback is based on existing data on nalmefene, the approved active ingredient embedded in TH104, including its safety profile and efficacy against opioid overdose as well as Tharimmune's pharmacokinetic data to support an "in silico" submission.

Tharimmune said it is seeking to develop TH104 for the additional proposed indication of "temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids."

The company is developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis.

Tharimmune shares rose over 5% in recent Monday trading.

Price: 1.44, Change: +0.07, Percent Change: +5.18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523992996"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523992996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523992996?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523992996","market":"sh","top_or_hot":-1,"title":"Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure","media":"MT Newswires Live","content":"<html><body><p> Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioid exposure.</p><p>The company said the FDA's feedback is based on existing data on nalmefene, the approved active ingredient embedded in TH104, including its safety profile and efficacy against opioid overdose as well as Tharimmune's pharmacokinetic data to support an \"in silico\" submission.</p><p>Tharimmune said it is seeking to develop TH104 for the additional proposed indication of \"temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids.\"</p><p>The company is developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis.</p><p>Tharimmune shares rose over 5% in recent Monday trading.</p><p>Price: 1.44, Change: +0.07, Percent Change: +5.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 23:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioid exposure.</p><p>The company said the FDA's feedback is based on existing data on nalmefene, the approved active ingredient embedded in TH104, including its safety profile and efficacy against opioid overdose as well as Tharimmune's pharmacokinetic data to support an \"in silico\" submission.</p><p>Tharimmune said it is seeking to develop TH104 for the additional proposed indication of \"temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids.\"</p><p>The company is developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis.</p><p>Tharimmune shares rose over 5% in recent Monday trading.</p><p>Price: 1.44, Change: +0.07, Percent Change: +5.18</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523992996","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523992996","pubTimestamp":1743434326,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","THAR":"Tharimmune Inc."},"translate_title":"Tharimmune表示FDA不要求对TH104针对阿片类药物暴露进行额外试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THAR":0.9},"content_text":"Tharimmune (THAR) said Monday the US Food and Drug Administration has advised that no additional clinical trials are required to support a new drug application for TH104 as a prophylaxis against opioid exposure.The company said the FDA's feedback is based on existing data on nalmefene, the approved active ingredient embedded in TH104, including its safety profile and efficacy against opioid overdose as well as Tharimmune's pharmacokinetic data to support an \"in silico\" submission.Tharimmune said it is seeking to develop TH104 for the additional proposed indication of \"temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering an area contaminated with high-potency opioids.\"The company is developing TH104 for the proposed indication of moderate-to-severe chronic pruritus in patients with primary biliary cholangitis.Tharimmune shares rose over 5% in recent Monday trading.Price: 1.44, Change: +0.07, Percent Change: +5.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}